Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score

Journal of Bone Oncology

Volumn 7, Issue , 2017, Pages 32-37

  Mariotti, Veronica ^a   Page, David B ^b   Davydov, Oksana ^c   Hans, Didier ^d   Hudis, Clifford A ^e   Patil, Sujata ^e   Kunte, Siddharth ^f   Girotra, Monica ^e   Farooki, Azeez ^e   Fornier, Monica N ^e  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Aromatase inhibitor; Breast cancer; Fracture risk assessment tool; FRAX ; Manitoba study; Osteopenia; Osteoporosis; TBS; Trabecular bone score

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MICROARCHITECTURE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY CANCER; FEMALE; FOLLOW UP; FRACTURE RISK ASSESSMENT TOOL; FRAGILITY FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; TRABECULAR BONE; TRABECULAR BONE SCORE; X RAY BONE DENSITOMETER;

EID: 85006802951     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2016.10.004     Document Type: Article

References (20)

1. Coates, A.S., Keshaviah, A., Thürlimann, B., Mouridsen, H., Mauriac, L., Forbes, J.F., Paridaens, R., Castiglione-Gertsch, M., Gelber, R.D., Colleoni, M., Láng, I., Mastro, L.D., Smith, I., Chirgwin, J., Nogaret, J.-M., Pienkowski, T., Wardley, A., Jakobsen, E.H., Price, K.N., Goldhirsch, A., Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. J. Clin. Oncol. 25 (2007), 486–492, 10.1200/JCO.2006.08.8617.
2. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)©Lancet 2015; 386: 1353–61.
3. Gnant, M., Pfeiler, G., Dubsky, P.C., Hubalek, M., Greil, R., Jakesz, R., Wette, V., Balic, M., Haslbauer, F., Melbinger, E., Bjelic-Radisic, V., Artner-Matuschek, S., Fitzal, F., Marth, C., Sevelda, P., Mlineritsch, B., Steger, G.G., Manfreda, D., Exner, R., Egle, D., Bergh, J., Kainberger, F., Talbot, S., Warner, D., Fesl, C., Singer, C.F., n.d. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. doi: 10.1016/S0140-6736(15)60995-3.
4. Schuit, S.C.E., van der Klift, M., Weel, A.E.A.M., de Laet, C.E.D.H., Burger, H., Seeman, E., Hofman, A., Uitterlinden, A.G., van Leeuwen, J.P.T.M., Pols, H.A.P., Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34 (2004), 195–202, 10.1016/j.bone.2003.10.001.
5. Szulc, P., Delmas, P.D., Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA 19 (2008), 1683–1704, 10.1007/s00198-008-0660-9.
6. Silva, B.C., Leslie, W.D., Resch, H., Lamy, O., Lesnyak, O., Binkley, N., McCloskey, E.V., Kanis, J.A., Bilezikian, J.P., Trabecular bone score: a noninvasive analytical method based upon the DXA image. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 29 (2014), 518–530, 10.1002/jbmr.2176.
7. Hans, D., Goertzen, A.L., Krieg, M.-A., Leslie, W.D., Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 26 (2011), 2762–2769, 10.1002/jbmr.499.
8. McCloskey, E.V., Odén, A., Harvey, N.C., Leslie, W.D., Hans, D., Johansson, H., Barkmann, R., Boutroy, S., Brown, J., Chapurlat, R., Elders, P.J., Fujita, Y., Glüer, C.-C., Goltzman, D., Iki, M., Karlsson, M., Kindmark, A., Kotowicz, M., Kurumatani, N., Kwok, T., Lamy, O., Leung, J., Lippuner, K., Ljunggren, Ö., Lorentzon, M., Mellström, D., Merlijn, T., Oei, L., Ohlsson, C., Pasco, J.A., Rivadeneira, F., Rosengren, B., Sornay-Rendu, E., Szulc, P., Tamaki, J., Kanis, J.A., A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res., 2015, 10.1002/jbmr.2734.
9. Task Force of the FRAX Initiative, Kanis, J.A., Hans, D., Cooper, C., Baim, S., Bilezikian, J.P., Binkley, N., Cauley, J.A., Compston, J.E., Dawson-Hughes, B., El-Hajj Fuleihan, G., Johansson, H., Leslie, W.D., Lewiecki, E.M., Luckey, M., Oden, A., Papapoulos, S.E., Poiana, C., Rizzoli, R., Wahl, D.A., McCloskey, E.V., Interpretation and use of FRAX in clinical practice. Osteoporos. Int 22 (2011), 2395–2411, 10.1007/s00198-011-1713-z.
10. Cosman, F., de Beur, S.J., LeBoff, M.S., Lewiecki, E.M., Tanner, B., Randall, S., Lindsay, R., Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA 25 (2014), 2359–2381, 10.1007/s00198-014-2794-2.
11. Silverman, S.L., Calderon, A.D., The utility and limitations of FRAX: A US perspective. Curr. Osteoporos. Rep 8 (2010), 192–197, 10.1007/s11914-010-0032-1.
12. Paterson, A.H.G., The role of bisphosphonates in early breast cancer. The Oncologist 11:Suppl 1 (2006), 13–19, 10.1634/theoncologist.11-90001-13.
13. Silva, B.C., Broy, S.B., Boutroy, S., Schousboe, J.T., Shepherd, J.A., Leslie, W.D., Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 2: Trabecular Bone Score. J. Clin. Densitom. Off. J. Int. Soc. Clin. Densitom. 18 (2015), 309–330, 10.1016/j.jocd.2015.06.008.
14. Harvey, N.C., Glüer, C.C., Binkley, N., McCloskey, E.V., Brandi, M.-L., Cooper, C., Kendler, D., Lamy, O., Laslop, A., Camargos, B.M., Reginster, J.-Y., Rizzoli, R., Kanis, J.A., Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 78 (2015), 216–224, 10.1016/j.bone.2015.05.016.
15. Pedrazzoni, M., Casola, A., Verzicco, I., Abbate, B., Vescovini, R., Sansoni, P., Longitudinal changes of trabecular bone score after estrogen deprivation: effect of menopause and aromatase inhibition. J. Endocrinol. Invest. 37 (2014), 871–874, 10.1007/s40618-014-0125-2.
16. Kalder, M., Hans, D., Kyvernitakis, I., Lamy, O., Bauer, M., Hadji, P., Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer. J. Clin. Densitom. Off. J. Int. Soc. Clin. Densitom. 17 (2014), 66–71, 10.1016/j.jocd.2013.03.003.
17. Hadji, P., Coleman, R.E., Wilson, C., Powles, T.J., Clézardin, P., Aapro, M., Costa, L., Body, J.-J., Markopoulos, C., Santini, D., Diel, I., Leo, A.D., Cameron, D., Dodwell, D., Smith, I., Gnant, M., Gray, R., Harbeck, N., Thurlimann, B., Untch, M., Cortes, J., Martin, M., Albert, U.-S., Conte, P.-F., Ejlertsen, B., Bergh, J., Kaufmann, M., Holen, I., Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann. Oncol 27 (2016), 379–390, 10.1093/annonc/mdv617.
18. Cuzick, J., Sestak, I., Forbes, J.F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., Mansel, R.E., von Minckwitz, G., Bonanni, B., Palva, T., Howell, A., IBIS-II investigators, Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet Lond. Engl 383 (2014), 1041–1048, 10.1016/S0140-6736(13)62292-8.
19. Bone, H.G., Chapurlat, R., Brandi, M.-L., Brown, J.P., Czerwinski, E., Krieg, M.-A., Mellström, D., Radominski, S.C., Reginster, J.-Y., Resch, H., Ivorra, J.A.R., Roux, C., Vittinghoff, E., Daizadeh, N.S., Wang, A., Bradley, M.N., Franchimont, N., Geller, M.L., Wagman, R.B., Cummings, S.R., Papapoulos, S., The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J. Clin. Endocrinol. Metab. 98 (2013), 4483–4492, 10.1210/jc.2013-1597.
20. MEDIMAPS-UK-WEB.pdf [WWW Document], n.d. URL 〈http://www.medimapsgroup.com/upload/MEDIMAPS-UK-WEB.pdf〉 (accessed 9.29.15).